MedTrace Logo

Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder (PTSD)

NCT00749203 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2018-02-14

Study results available
· View outcomes & findings →

Summary

The objective of the proposed study is to test if a single IV dose of ketamine (0.5 mg/kg) decreases symptoms of PTSD.

Conditions

Interventions

DRUG

Midazolam

single dose 0.045 mg/kg IV infused over 40 minutes

DRUG

Ketamine

Single dose 0.5 mg/kg IV (in the vein) infused over 40 minutes

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • Dennis Charney

    lead OTHER

Principal Investigators

  • Dennis Charney, MD · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2013-09-30
Completion
2013-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00749203 on ClinicalTrials.gov